Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cue Biopharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CUE
Nasdaq
8731
https://www.cuebiopharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cue Biopharma Inc
2 “Strong Buy” Penny Stocks With Over 200% Upside on the Horizon
- Mar 28th, 2023 2:45 pm
Cue Biopharma, Inc. (NASDAQ:CUE) Q4 2022 Earnings Call Transcript
- Mar 24th, 2023 11:28 am
Q4 2022 Cue Biopharma Inc Earnings Call
- Mar 22nd, 2023 11:37 am
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
- Mar 21st, 2023 8:10 pm
Cue Biopharma to Host Business Update Call and Webcast
- Mar 15th, 2023 12:00 pm
Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences
- Mar 1st, 2023 1:00 pm
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
- Feb 22nd, 2023 1:00 pm
Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting
- Feb 16th, 2023 3:30 pm
Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board
- Feb 16th, 2023 1:00 pm
Investors in Cue Biopharma (NASDAQ:CUE) have unfortunately lost 81% over the last three years
- Feb 14th, 2023 10:49 am
Cue Biopharma to Present at Two February 2023 Scientific Conferences
- Feb 1st, 2023 1:00 pm
Cue Biopharma Announces Chief Medical Officer Transition
- Jan 23rd, 2023 1:00 pm
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
- Nov 22nd, 2022 1:00 pm
Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)
- Nov 17th, 2022 2:00 pm
Cue Biopharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
- Nov 16th, 2022 10:33 am
Cue Biopharma Reports Third Quarter 2022 Financial Results
- Nov 14th, 2022 9:01 pm
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
- Nov 14th, 2022 1:20 pm
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
- Nov 10th, 2022 2:00 pm
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
- Nov 9th, 2022 1:00 pm
Cue Biopharma, Inc. (NASDAQ:CUE) drops to US$91m and insiders who purchased earlier this year lose another US$33k
- Oct 17th, 2022 4:18 pm
Scroll